Midterm election history, healthcare sector rotation, and specific stock analysis in healthcare ETF
Summary
The host and guest discuss historical market returns following midterm elections, noting positive trends six and twelve months post-event. They analyze the Harvest Healthcare ETF's strategy, which uses an equally weighted approach and covered calls to generate an 8-9% yield. The conversation covers political risks like drug pricing and Medicare for All, arguing that managed care companies may benefit from expanded access. Specific stock opinions include selling Pfizer due to R&D issues, holding Boston Scientific and Stryker despite valuation pressures, and viewing UnitedHealth as a turnaround opportunity.
Episode sections
- 0:03 – 4:32
Healthcare Sector Outlook and Midterm Elections
Discussion on historical market returns post-midterm elections and long-term drivers like aging populations.
- 4:32 – 8:15
Fund Strategy and ETF Mechanics
Description of the Harvest Healthcare ETF's equally weighted strategy, covered call income, and 8-9% yield.
- 8:15 – 20:34
Policy Risks and Managed Care
Analysis of political risks including Medicare for All and drug pricing, and the resilience of managed care companies.
- 20:34 – 25:16
Mailbag: Pfizer and Bristol-Myers Squibb
Investor questions addressed regarding Pfizer's value trap status and Bristol-Myers Squibb's deep value potential.
- 25:16 – 26:37
Mailbag: Moderna and Oncology Innovation
Discussion on Moderna's therapeutic vaccine for melanoma and valuation constraints preventing fund ownership.
- 26:37 – 29:10
Merck, mRNA Vaccines, and Political Sentiment
Merck's K-Truda combination therapy results and the impact of political sentiment on vaccine makers.
- 29:10 – 33:05
CVS Health Spin-off and Market Reaction
Skepticism regarding CVS Health's spin-off of its drugstore business and the value of its managed care segment.
- 33:05 – 35:28
Bausch Health Debt Concerns
Reasons for avoiding Bausch Health due to high debt levels relative to sales.
- 35:28 – 38:03
Zoetis: Competition and Consumer Sensitivity
Exit from Zoetis due to competition for Simparica and economic sensitivity of pet care spending.
- 38:03 – 41:51
Boston Scientific: Valuation and Competitive Landscape
Holding Boston Scientific despite valuation compression from guidance cuts and competition in PFA technology.
- 41:51 – 45:04
Stryker: Orthopedics Slowdown and Cyber Attack
Analysis of Stryker's orthopedic focus, transient issues from guidance cuts and cyber attacks, and low valuation.
- 45:04 – 48:00
AbbVie: Off-Patent Transition and Innovation
AbbVie's successful transition post-Humira patent expiration through acquisitions and new blockbuster drugs.
- 48:00 – 53:38
UnitedHealth Group: Managed Care Turnaround
Viewing UnitedHealth as a turnaround opportunity despite regulatory headwinds and DOJ investigations.
Assets discussed
| Asset | Kind | Stance | Context |
|---|---|---|---|
| ELI LILLY & CoLLY | equity | bullish | Now, in this more recent cycle, it really comes down to Eli Lilly, which we own. |
| PFIZER INCPFE | equity | neutral | Now, Pfizer Moderna also got caught up in Maha, make America healthy again and post the midterms. |
| Moderna, Inc.MRNA | equity | neutral | Now, Pfizer Moderna also got caught up in Maha, make America healthy again and post the midterms. |
| Zoetis Inc.ZTS | equity | bearish | And so when we peeled back the layer, um, the layers on the fundamentals, their animal, sorry, their companion um side, we start to think about a consumer that is, you know, feeling it at the pumps, feeling it, you know, at the grocery stores. |
| JOHNSON & JOHNSONJNJ | equity | neutral | And so um, you know, wonderful new technology, but Medtronic and Johnson Johnson are coming in. |
“Stance” is how the speakers talked about the asset, not a recommendation.
Claims worth verifying
Healthcare has the second highest earnings growth forecast for 2027, next to tech.
Unidentified speaker ·19:03
How to verify: Check consensus earnings growth estimates for the S&P 500 Healthcare sector versus the S&P 500 Information Technology sector for 2027 on financial data platforms like Bloomberg or FactSet.
85% of the time, the market is positive six months after midterm elections, and 100% of the time it is positive twelve months out.
Unidentified speaker ·5:08
How to verify: Analyze historical S&P 500 performance data surrounding all US midterm elections over the past 90 years to calculate the percentage of positive returns at the 6-month and 12-month marks post-election.
The Harvest Healthcare ETF has $2.2 billion in assets and is equally weighted across 20 companies.
Unidentified speaker ·3:31
How to verify: Review the fund's latest fact sheet or annual report from Harvest Capital Management to confirm assets under management and portfolio composition.
The ETF pays a distribution of exactly six cents per month, yielding approximately 8-9%.
Unidentified speaker ·15:37
How to verify: Check the fund's distribution history and current price on the fund provider's website or financial data terminals to calculate the trailing twelve-month yield.
Pfizer paid a huge premium for the Seagen acquisition, described as around 20 times revenue.
Unidentified speaker ·21:50
How to verify: Review Pfizer's SEC filings (Form 8-K) regarding the Seagen acquisition to find the purchase price multiple relative to Seagen's trailing or forward revenue.
Bristol-Myers Squibb's earnings multiple expanded from seven times to nine and a half times earnings.
Unidentified speaker ·24:58
How to verify: Compare Bristol-Myers Squibb's P/E ratio from one year ago to the current P/E ratio using historical stock data from Yahoo Finance or Bloomberg.
Moderna's cancer vaccine is in Phase 2 trials for melanoma.
Unidentified speaker ·25:56
How to verify: Search clinical trial registries (e.g., ClinicalTrials.gov) for Moderna's melanoma vaccine candidates to verify the current phase of development.
United Health, Elevent (likely Eleven), and CVS have businesses that administer government healthcare programs on a per-person basis.
Unidentified speaker ·11:11
How to verify: Review the annual reports or business segment disclosures of UnitedHealth Group, CVS Health, and Elevent (if referring to a specific entity like Optum or a typo for another insurer) to confirm their role in administering Medicare/Medicaid.
The ETF has a covered call strategy which gives up upside for income.
Unidentified speaker ·15:11
How to verify: Read the prospectus of the Harvest Healthcare ETF to confirm the use of options strategies, specifically covered calls, and their impact on performance relative to the underlying index.
Correlations between healthcare and tech stocks have gone negative in the past four to five months.
Unidentified speaker ·17:44
How to verify: Calculate the rolling three-month correlation coefficient between the XLV (Health Care Select Sector SPDR Fund) and XLK (Technology Select Sector SPDR Fund) using historical price data.
K-Truda combination therapy showed a 45% improvement rate over K-Truda alone.
Speaker 2 ·26:37
How to verify: Check Merck's clinical trial data or press releases regarding K-Truda combination studies.
US vaccine rates are falling.
Speaker 1 ·27:40
How to verify: Review CDC or public health department data on US vaccination rates.
Health and Human Services staff decreased from 95,000 to 72,000 in the past two years.
Speaker 2 ·28:24
How to verify: Check HHS workforce reports or government employment statistics.
CVS Health plans to spin off its drugstore business.
Speaker 1 ·29:13
How to verify: Review CVS Health's recent earnings announcements or SEC filings.
Bausch Health has over $20 billion in debt on $11 billion in sales.
Speaker 2 ·34:32
How to verify: Check Bausch Health's latest financial statements or SEC filings.
Apotex IPO price was $24 and is now around $34.
Speaker 2 ·35:25
How to verify: Check Apotex's IPO prospectus and current stock price.
Boston Scientific's valuation multiple was cut in half from ~36x to ~18x.
Speaker 1 ·40:24
How to verify: Check Boston Scientific's historical P/E ratios and current stock price.
AbbVie's Humira generated $20+ billion in annual sales before patent expiration.
Speaker 2 ·46:04
How to verify: Check AbbVie's historical financial reports or industry analyses on Humira sales.
UnitedHealth Group insures 50 million lives in the US.
Speaker 2 ·50:07
How to verify: Check UnitedHealth Group's investor presentations or annual reports.
UnitedHealth Group raised its forecast after a fabulous quarter.
Speaker 2 ·50:52
How to verify: Check UnitedHealth Group's recent earnings releases or press statements.
Do your own research
- Verify historical market return data for post-midterm election periods using S&P 500 or broader market indices.
- Review the Harvest Healthcare ETF's prospectus for details on the covered call strategy, yield calculation, and turnover rate.
- Analyze Pfizer's recent R&D pipeline updates and patent expiration timelines for key drugs.
- Check Merck's clinical trial data for K-Truda combination therapy results and approval status.
- Examine Bausch Health's balance sheet for debt maturity schedules and interest coverage ratios.
- Review Zoetis's competitive landscape reports for generic entry timelines of Simparica competitors like Alanco.
- Assess UnitedHealth Group's regulatory filings regarding DOJ investigations and changes in medical loss ratios.
- Compare Boston Scientific's valuation multiples against peers like Medtronic and Johnson & Johnson in the device sector.
Full transcriptexpand
- 0:03
- Unidentified speaker: Next attack.
- 0:05
- Unidentified speaker: Healthcare has the the second highest earnings growth forecast for 2027.
- 0:09
- Unidentified speaker: We're still very bullish.
- 0:11
- Unidentified speaker: Healthcare stocks are on fire.
- 0:12
- Unidentified speaker: Can the rally keep going?
- 0:13
- Unidentified speaker: We asked the man who runs Canada's biggest healthcare fund.
- 0:16
- Unidentified speaker: I'm wondering how you think about the sector as it relates to the midterms.
- 0:20
- Unidentified speaker: Boston Scientific.
- 0:22
- Unidentified speaker: Should I keep holding?
- 0:23
- Unidentified speaker: I've owned them before and I own it right now, and it has been a painful spot to be.
- 0:27
- Unidentified speaker: And the Pfizer, I would say also, I would call it a value play.
- 0:32
- Unidentified speaker: And so not a value trap?
- 0:34
- Unidentified speaker: I I it's been a value trap.
- 0:36
- Unidentified speaker: At some point I'm gonna buy it again.
- 0:38
- Unidentified speaker: Um and part of that so that I have to stop defending why I don't own it.
- 0:42
- Unidentified speaker: Their AFib treatment, which is um the electro uh uh what's the word I'm looking for?
- 0:49
- Unidentified speaker: I'm having a little bit of a moment here.
- 0:51
- Unidentified speaker: It's okay, it's not med school.
- 0:52
- Unidentified speaker: You can just investors choose to follow the crowd by chasing returns rather than anticipating them.
- 1:05
- Unidentified speaker: The mutual fund and ETF strategies offered by Guardian Capital LP don't seek to follow trends, but find long-term opportunities.
- 1:12
- Unidentified speaker: Standing apart from the crowd is not always easy.
- 1:15
- Unidentified speaker: But for more than six decades, Guardian Capital has helped investors navigate changing markets through independent thinking, active management, and disciplined risk oversight.
- 1:24
- Unidentified speaker: Guardian Capital LP, following conviction, not the crowd.
- 1:28
- Unidentified speaker: Contact your advisor today and ask about Guardian Capital's funds and ETFs and visit their website for more information.
- 1:33
- Unidentified speaker: Guardian Capital.com.
- 1:38
- Unidentified speaker: The content provided in this podcast is for informational purposes only and does not constitute financial investment or professional advice.
- 1:45
- Unidentified speaker: The views expressed by the host and the guests are their own and do not necessarily reflect the opinions of any organization or company.
- 1:51
- Unidentified speaker: The host and guest may maintain positions in any securities discussed on the podcast.
- 1:55
- Unidentified speaker: Always consult with a qualified financial advisor or professional before making any investment decisions.
- 2:00
- Unidentified speaker: In this episode, we discuss United Health, Eli Lilly, CVS, Pfizer, and Moderna, which are all stocks that I own.
- 2:07
- Unidentified speaker: Hey everyone, welcome to a brand new episode of In the Money with Amber Canmar.
- 2:10
- Unidentified speaker: I'm gonna call this episode the I Told You So episode because it's all about healthcare.
- 2:15
- Unidentified speaker: And how many times have we done a healthcare episode?
- 2:18
- Unidentified speaker: And I always chastise you, those that are listening, that you know, it's never one of our best rated episodes, but you can have some really astonishing returns in healthcare.
- 2:28
- Unidentified speaker: And if you listen to my disclosures, you know that I am a sucker for the healthcare sector, especially when these companies run into trouble.
- 2:38
- Unidentified speaker: And a lot of times I have to disclose uh the stupid investments that I have made.
- 2:43
- Unidentified speaker: And this time I really get to brag because I bought United Health, Eli Lilly, United's up, I'm up 30%.
- 2:51
- Unidentified speaker: Eli Lilly, I'm up 75%.
- 2:53
- Unidentified speaker: CVS, also a broken story.
- 2:56
- Unidentified speaker: I bought, I'm up 45%.
- 2:58
- Unidentified speaker: And Moderna, which I bought at the beginning of the year, I'm up 400%.
- 3:03
- Unidentified speaker: Um, so all this to say, uh-huh.
- 3:06
- Unidentified speaker: I told you so.
- 3:07
- Unidentified speaker: I hope you participated because we in the past have had some great guests.
- 3:11
- Unidentified speaker: Um, I'm still down on Pfizer.
- 3:13
- Unidentified speaker: That's just like the way the world works.
- 3:14
- Unidentified speaker: I don't make the rules, but I don't know that Pfizer will ever get up, but I'm still um hanging on.
- 3:20
- Unidentified speaker: On this episode, we've got Paul McDonald of Harvest.
- 3:23
- Unidentified speaker: He runs an ETF that's active-ish as he described it.
- 3:27
- Unidentified speaker: Um it's kind of rules-based, but they do change names occasionally.
- 3:31
- Unidentified speaker: It owns about 20 large cap US healthcare um names, $2.2 billion in assets.
- 3:37
- Unidentified speaker: And what's interesting is since June, the ETF went from losing money, that means people pulling out money from the ETF, to now seeing inflows.
- 3:48
- Unidentified speaker: Healthcare is benefiting from a rotation.
- 3:51
- Unidentified speaker: The midterms are part of it, especially with a democratic suite, but it's not the only factor.
- 3:56
- Unidentified speaker: So we talk about what can really lead to longevity and whether on the back of this run-up, you know, all the easy money has been made.
- 4:05
- Unidentified speaker: So um it's a really fascinating discussion.
- 4:08
- Unidentified speaker: There's a lot of nuance there.
- 4:09
- Unidentified speaker: And because I really value full disclosure, I do want to tell you that Harvest is not one of our sponsors, but we've had discussions in the past about them being a sponsor.
- 4:20
- Unidentified speaker: Um, I don't think that colored my interview at all, but you know, I like to be squeaky clean.
- 4:24
- Unidentified speaker: So I'm just letting you know.
- 4:25
- Unidentified speaker: Let's get into it.
- 4:32
- Unidentified speaker: Paul McDonald, thank you so much for joining us on the podcast.
- 4:36
- Unidentified speaker: Great to be here, Amber.
- 4:37
- Unidentified speaker: You run Canada's largest healthcare fund, $2.2 billion in the Harvest Healthcare ETF.
- 4:43
- Unidentified speaker: And it's a great day to have you because we're one day removed from the midterm elections in the US.
- 4:48
- Unidentified speaker: And healthcare, I mean, it was kind of running up into the midterm elections, and it's seen as a big winner in this sort of Democrat sweep.
- 4:57
- Unidentified speaker: And I'm wondering how you think about the sector as it relates to the midterms.
- 5:02
- Unidentified speaker: Specific to the midterms, um, you know, I I guess I would look at it and say it's the passing of the event.
- 5:08
- Unidentified speaker: You know, from our perspective, you look back, you know, over the past uh past 90 years, I think, on on midterms, and there's there's really no correlation coming into the into the midterms, but uh 85% of the time, six months out after the market's positive, and 12 months out, 100% of the time it's positive.
- 5:28
- Unidentified speaker: So from our perspective, the this is a passing of the event.
- 5:31
- Unidentified speaker: There's there's gonna be some gyrations, you know.
- 5:34
- Unidentified speaker: Does this impact, you know, managed care a little bit more?
- 5:38
- Unidentified speaker: You know, what happens with the Affordable Care Act?
- 5:40
- Unidentified speaker: I think, you know, from our perspective, it was really health care on the shorter term.
- 5:45
- Unidentified speaker: Yes, you look at the chart and say, wow, it's it's actually been performing well.
- 5:48
- Unidentified speaker: You extend that out and compare it to the broader market, though.
- 5:51
- Unidentified speaker: It has not been an area that uh has gotten a lot of attention up until call it the past four or five months.
- 5:58
- Unidentified speaker: You know, I'm so glad you brought that up because we'll do healthcare episodes.
- 6:02
- Unidentified speaker: And I think healthcare is so fascinating.
- 6:04
- Unidentified speaker: There's political, there's policy, there's individual stories, there's entrepreneurialism.
- 6:08
- Unidentified speaker: And I feel like, you know, those aren't our most popular episodes, I'll be frank about that.
- 6:14
- Unidentified speaker: But as you said, now we've seen a rotation into this sector.
- 6:19
- Unidentified speaker: I wonder if you see that from a fund flows perspective.
- 6:22
- Unidentified speaker: Like, is interest actually picking up?
- 6:24
- Unidentified speaker: And now that we have seen a pickup in healthcare, is it still exciting?
- 6:29
- Unidentified speaker: You know, people come on and say, oh, these are generationally low multiples.
- 6:32
- Unidentified speaker: Is that still the case?
- 6:34
- Unidentified speaker: So I would say yes.
- 6:36
- Unidentified speaker: Um, and certainly we we get really excited about the medium longer term.
- 6:40
- Unidentified speaker: There's no question, as you pointed out, the the technological innovation, we see it with AI, but within healthcare, it is just fascinating what we're seeing, whether it's drug development and technological innovation in medical devices and tools.
- 6:54
- Unidentified speaker: I'm not, I'm not talking about our eye watch.
- 6:55
- Unidentified speaker: It's exciting.
- 6:56
- Unidentified speaker: I get to measure my sleep.
- 6:57
- Unidentified speaker: Um, but but you know, really robotic assisted surgeries, things like that.
- 7:01
- Unidentified speaker: Um, the aging populations, though, that's a permanent non-cyclical driver.
- 7:06
- Unidentified speaker: And so as we age, we spend exponentially more money on our healthcare needs.
- 7:11
- Unidentified speaker: And so you couple that with some developing markets, you know, the longer term of technological innovation, developing markets and aging populations.
- 7:19
- Unidentified speaker: That's really exciting.
- 7:21
- Unidentified speaker: But to your point, in the shorter term, absolutely we have seen rotations.
- 7:26
- Unidentified speaker: And there's all kinds of technical indicators that you can look at that sort of, okay, it's starting, it's lagging, it's leading 12 weeks.
- 7:32
- Unidentified speaker: Um, and we have seen that in the very short term.
- 7:35
- Unidentified speaker: Uh, in in our fund, you know, we've been very fortunate to have consistent flows over the past three years.
- 7:41
- Unidentified speaker: In the US, though, when you look at ETF flows, we really were in negative outflows um up until about June this year.
- 7:50
- Unidentified speaker: So meaning with meaningful people were using it as a source of capital.
- 7:54
- Unidentified speaker: And now we've seen that shift in probably the mid-summertime.
- 7:58
- Unidentified speaker: So and that's an important time frame because June is almost when the AI trade sort of stalled out, right?
- 8:04
- Unidentified speaker: And and investors were looking for a different home and they found healthcare.
- 8:08
- Unidentified speaker: But I do want to bring it back to policy because healthcare is probably the easiest punching bag if you're a politician.
- 8:15
- Unidentified speaker: Um, you know, we saw it eight, nine years ago when it actually was the Democrats led under um, I think it was Hillary Clinton at the time in her role, uh, talking about while she was campaigning, sorry, uh, talking about drug prices, right?
- 8:31
- Unidentified speaker: And you saw uh the pharma's sell off.
- 8:34
- Unidentified speaker: Um, we see it when it comes to managed care.
- 8:37
- Unidentified speaker: How much is the government willing to pay for things like Medicare?
- 8:41
- Unidentified speaker: So you can see a bit of a squeeze.
- 8:43
- Unidentified speaker: Um, are there any key policy initiatives that you're watching for that are important to this sector right now?
- 8:51
- Unidentified speaker: Always policy initiatives.
- 8:52
- Unidentified speaker: And I I haven't heard it called the punching bag, but we we we use lightning rod.
- 8:56
- Unidentified speaker: But I'll tell you there's been times over the past uh past 10 plus years that I've covered the sector.
- 9:00
- Unidentified speaker: I felt like I was the punching bag when some of these policies or a politician comes out and says Medicare for all, and the sector sells off.
- 9:07
- Unidentified speaker: And it's it's like, okay, to affect that, here's the 500 things that need to happen, of which number one and two are already very difficult.
- 9:16
- Unidentified speaker: So to affect a lot of these, you know, um almost it seems like they're easy to do.
- 9:24
- Unidentified speaker: They're actually very complicated, and it's a very integrated, complicated uh system.
- 9:29
- Unidentified speaker: So, you know, the with the passing of the midterms Democrats coming back in, we do start to hear a little bit more.
- 9:36
- Unidentified speaker: Okay, it's going to be Medicare for all.
- 9:38
- Unidentified speaker: Um, and to your point on uh going back to the Obama era when we actually had the Affordable Care Act come in, you know, we we heard the whole street, uh, do you know what healthcare's dead?
- 9:49
- Unidentified speaker: Turns out it was like one of the best performing subsectors under his presidency.
- 9:53
- Unidentified speaker: And so, you know, these sort of notions that the policies are going to be detrimental to the sector, you know, that's not what we've seen.
- 10:01
- Unidentified speaker: It does cause some shorter term volatility at times.
- 10:04
- Unidentified speaker: And so we're keeping an eye on that.
- 10:05
- Unidentified speaker: But there's been some initiatives, you know, under the Inflation Reduction Act, drug pricing, where, you know, Medicare is negotiating drug pricing, you know, some of the some of the changes under Medicaid where, you know, you're required to work for Medicaid, you know, coming out 20, 2030, 20, 2032, they likely go away, which means, okay, we're going to have maybe some pressure on some premiums at the insurance companies, but we're going to have more people.
- 10:32
- Unidentified speaker: And so, you know, you kind of wash that out.
- 10:34
- Unidentified speaker: And I think it comes back to what I said at the start, which was this is really a little bit of a clearing event for the sector.
- 10:42
- Unidentified speaker: So we have a little bit more clarity.
- 10:44
- Unidentified speaker: A little bit.
- 10:44
- Unidentified speaker: It's still on certain.
- 10:46
- Unidentified speaker: Help our and um viewers understand why expanded um health care access through insurance would be a negative for some of the publicly traded companies.
- 10:58
- Unidentified speaker: So so think about think about um those that are actually so in in the US, uh, Medicare and Medicaid are funded by or administered by uh companies.
- 11:11
- Unidentified speaker: So think about United Health.
- 11:12
- Unidentified speaker: There's some not prof not-for-profit, there's some government, uh, government-run um uh organizations that do that.
- 11:18
- Unidentified speaker: But generally think about companies like United Health and um Elevents and you know, uh even CVS within their ATNA business.
- 11:28
- Unidentified speaker: And so they administer on a per person basis the the government's healthcare program.
- 11:35
- Unidentified speaker: So if we start to hear about, you know, the Affordable Care Act um uh tax implications of uh say, okay, do you know what this we're no longer giving tax credits?
- 11:47
- Unidentified speaker: Um, you know, that might mean fewer people are going to be, you know, accessing Medicare.
- 11:53
- Unidentified speaker: Um, or if they say, Do you know what we actually have to have the insurance companies pay part of that?
- 11:59
- Unidentified speaker: There's going to be some sharing of what these, you know, credits look like, then you know, that would have a financial impact.
- 12:06
- Unidentified speaker: No, the flip side is that because of those tax incentives, more people are coming.
- 12:10
- Unidentified speaker: More people are coming.
- 12:11
- Unidentified speaker: So that's kind of the trade-off.
- 12:13
- Unidentified speaker: And you really won't know that until each, each, as each year passes.
- 12:16
- Unidentified speaker: So as you structure the portfolio, and I guess I should ask, is the is the healthcare ETF actively managed?
- 12:23
- Unidentified speaker: It is, yes.
- 12:24
- Unidentified speaker: So I'll astracize active because the turnover tends to be very low.
- 12:29
- Unidentified speaker: Um, we and we do have very firm goalposts.
- 12:32
- Unidentified speaker: And that's that's by design.
- 12:33
- Unidentified speaker: I've been managing money now for 20, almost 25 years.
- 12:37
- Unidentified speaker: And I've seen so many managers, whether it's whether it's the large cap energy manager that ends up being in small cap gas stocks, uh, or the large cap healthcare manager that ends up being a you know a mid-cap biotech specialist, um, we've got really firm goalposts on what we can invest in.
- 12:52
- Unidentified speaker: And so it has to be large, even mega cap.
- 12:56
- Unidentified speaker: Uh, we're mandated to be diversified, uh, and we have to meet some financial metrics.
- 13:01
- Unidentified speaker: And so, what that does for us, um, and we have to have 20 companies.
- 13:04
- Unidentified speaker: So we're we're equally weighted at 20 companies, and we go through that process every quarter.
- 13:09
- Unidentified speaker: And so, what that does for us is it makes sure that every quarter we're reviewing each one of our companies and they still have to meet these various metrics.
- 13:18
- Unidentified speaker: But because of that front-end analytics that we do, the turnover tends to be relatively low.
- 13:24
- Unidentified speaker: You have um a lot of choice in healthcare.
- 13:27
- Unidentified speaker: You can buy an insurance company, you could buy a medical device company, you could buy a pharmaceutical, you could, but you could buy a biotech.
- 13:35
- Unidentified speaker: Are those, I think those are the four main categories?
- 13:38
- Unidentified speaker: Effectively, yeah.
- 13:38
- Unidentified speaker: Um, how do you rank the attractiveness right now?
- 13:41
- Unidentified speaker: Like we're we're without naming names, because I know you brought a couple of names for us, like what sectors are the most interesting within healthcare?
- 13:49
- Unidentified speaker: Great question.
- 13:50
- Unidentified speaker: And I'll answer it being honest.
- 13:52
- Unidentified speaker: Uh, because if you had asked me this at the start of the year, I would have actually said, do you know what the med tech names?
- 13:58
- Unidentified speaker: They they're gonna keep running.
- 14:00
- Unidentified speaker: They they look wonderful.
- 14:01
- Unidentified speaker: The charts look great, their valuations, the growth.
- 14:04
- Unidentified speaker: And the pharma, okay, Lily looks still really, really good, but you know, Merck, I don't know.
- 14:09
- Unidentified speaker: You know, fast forward, you know, 10 months, my best performing stocks have been the pharma.
- 14:15
- Unidentified speaker: The sector has a really funny way, you know, like I said, 10 plus years I've covered the sector, has a funny way of having these little under-the-surface shifts.
- 14:24
- Unidentified speaker: And so uh I'm gonna come back to the start of the year now that the med tech have been the worst performers.
- 14:29
- Unidentified speaker: Uh, and I really do think there's some great value within the in the med techs.
- 14:33
- Unidentified speaker: And then adjacent to that, you would have some of the tools and diagnostics companies.
- 14:38
- Unidentified speaker: So, you know, companies that make the uh the big lab equipment, et cetera.
- 14:41
- Unidentified speaker: But definitely some of the uh some of the medical device companies.
- 14:45
- Unidentified speaker: And when you look at the performance of the ETF, um, you know, it's up strongly, but it's lagged the S P 500 healthcare index.
- 14:51
- Unidentified speaker: And I'm curious as you think about your positioning relative to what's in that index, like what are some of the reasons?
- 14:57
- Unidentified speaker: You know, where are you offside?
- 14:59
- Unidentified speaker: And do you look to reposition?
- 15:01
- Unidentified speaker: Is it because you don't have some of those smaller, maybe more momentum-driven biotech names?
- 15:07
- Unidentified speaker: Um not in this cycle.
- 15:09
- Unidentified speaker: That that could be the case over time.
- 15:11
- Unidentified speaker: And so I think really important for us is to remind people we have a cover call strategy.
- 15:16
- Unidentified speaker: So that's that's number one.
- 15:18
- Unidentified speaker: So you have you do give up some of the upside, and we can talk about it.
- 15:20
- Unidentified speaker: But then you get income.
- 15:22
- Unidentified speaker: But then you get income.
- 15:23
- Unidentified speaker: And what's the yield?
- 15:24
- Unidentified speaker: I it's uh around 9%, depending on when when one buys at eight, eight to nine.
- 15:28
- Unidentified speaker: It's been the same distribution.
- 15:29
- Unidentified speaker: We we increased it once, uh, I guess 11 years running.
- 15:32
- Unidentified speaker: So you're paying, we're paying just uh around six cents a month.
- 15:35
- Unidentified speaker: Um, well, not around.
- 15:37
- Unidentified speaker: So it's exactly six cents.
- 15:38
- Unidentified speaker: It was 5.83.
- 15:39
- Unidentified speaker: Okay.
- 15:40
- Unidentified speaker: We're now six cents, and we've been doing that for 10 plus years.
- 15:43
- Unidentified speaker: Uh, and so you know, when it when I think about relative performance, so there's times look when the when the when I call it the smids, the small and mid-cap names are really ripping.
- 15:52
- Unidentified speaker: Uh we're going to lag.
- 15:54
- Unidentified speaker: There's no question.
- 15:55
- Unidentified speaker: Um, you know, that's just the nature of we don't want those really higher torque.
- 15:59
- Unidentified speaker: Um, you know, we we've you know, we don't we don't want we're gonna miss the rockets to avoid the torpedoes, as one says.
- 16:05
- Unidentified speaker: Now, in this more recent cycle, it really comes down to Eli Lilly, which we own.
- 16:09
- Unidentified speaker: It's our only uh exposure, direct exposure to the to the glip ones, you know, relative to Novo, um, the other dominant player.
- 16:17
- Unidentified speaker: Yeah.
- 16:18
- Unidentified speaker: Um, but because the SP is is cap weighted, I want to say it's you know, it might be 15% of that index where we're equally weighted.
- 16:26
- Unidentified speaker: So I see that that would be the skew in the their shorter term.
- 16:29
- Unidentified speaker: Uh for people who, you know, our audience actually loves income.
- 16:32
- Unidentified speaker: Um, but they but you know, they've been increasingly finding it maybe more in commodities, or they think about the financials.
- 16:38
- Unidentified speaker: So as you talk to investors about the role of healthcare in their portfolio, what do you say?
- 16:44
- Unidentified speaker: Oh, it has to has to be a component.
- 16:46
- Unidentified speaker: And look, when we think about, we were talking about this earlier, you know, about the market itself.
- 16:51
- Unidentified speaker: You're right.
- 16:52
- Unidentified speaker: The market's actually been been marching time.
- 16:54
- Unidentified speaker: Markets correct two ways, either in price, they go down, or time in which, you know, the earnings catch up and the market rotates.
- 17:02
- Unidentified speaker: And so that's really what we've seen over call it the past six, eight months here is the market is rotating.
- 17:08
- Unidentified speaker: And so just like within my fund, you know, trying to pick those exact moments of when, you know, when energy is going to lead or when healthcare is actually going to start to lead, um, those are that's really difficult to do to so to have some exposure.
- 17:22
- Unidentified speaker: But in particular, given where we're at in the cycle, we're still very bullish.
- 17:26
- Unidentified speaker: We still think growth is intact.
- 17:27
- Unidentified speaker: We think the earnings across the AI cycle is not done.
- 17:31
- Unidentified speaker: And so we want to be allocated there, but absolutely allocating to more defensive areas.
- 17:37
- Unidentified speaker: And you see it, it's it's a really interesting dichotomy in the past, I want to say four or five months here, where we've seen the correlations.
- 17:44
- Unidentified speaker: We measured in three-month correlations, but the correlations with healthcare and tech has actually gone negative.
- 17:50
- Unidentified speaker: And what that means is I sit right beside my tech manager.
- 17:54
- Unidentified speaker: And so I can come in and look at his face.
- 17:56
- Unidentified speaker: Those guys are never at the same mouth.
- 17:58
- Unidentified speaker: Well, every now and again I'll be like, Can you believe healthcare is up 2%?
- 18:01
- Unidentified speaker: And I'll look, he'll look over and say, Oh, let me translate that to tech.
- 18:04
- Unidentified speaker: It's up 20%.
- 18:05
- Unidentified speaker: And he goes, Oh, I could have been, I can tell by his face whether tech's up or down, uh, whether healthcare is going to be up or down.
- 18:12
- Unidentified speaker: So healthcare has sort of become the anti um momentum-driven AI trade.
- 18:17
- Unidentified speaker: A little bit, yeah, a little bit.
- 18:18
- Unidentified speaker: And so that rotation has been underway for some time now.
- 18:22
- Unidentified speaker: Uh and you think will continue?
- 18:24
- Unidentified speaker: I think I think it does.
- 18:25
- Unidentified speaker: I think that I think it does continue, but I think also that, you know, we're in a bull market.
- 18:29
- Unidentified speaker: It's really tough to be bullish here.
- 18:31
- Unidentified speaker: Um, but we're, you know, we're we're very bullish.
- 18:34
- Unidentified speaker: But I think there's absolutely some catch up here as we've seen that rotation.
- 18:38
- Unidentified speaker: I think healthcare continues to I wouldn't even say lead, but when we look at 2027, um, we had a tough earnings year in healthcare.
- 18:46
- Unidentified speaker: You know, United Health was uh we that was something from 2026 that really caused some drag on the sector.
- 18:52
- Unidentified speaker: And we're effectively flat up a little bit for 2026 earnings.
- 18:56
- Unidentified speaker: But next to tech, healthcare has the the second highest earnings growth forecast for 2027.
- 19:03
- Unidentified speaker: As and I think what we've seen in this earnings season is as that's being validated, we're starting to see the market go, oh, do you know what?
- 19:12
- Unidentified speaker: We we want to be allocating into this area that's actually starting to look like it's going to hit these estimates.
- 19:17
- Unidentified speaker: All right, let's see if we can find some of those opportunities and dip into the mailbag.
- 19:22
- Unidentified speaker: The mailbag is brought to you by Hamilton ETFs.
- 19:25
- Unidentified speaker: For the past decade, Hamilton has focused on taking sophisticated investment ideas and turning them into ETFs that are simple, transparent, and easy for Canadians to own.
- 19:35
- Unidentified speaker: Now, today, Hamilton is Canada's largest independent ETF provider with more than $17 billion in assets under management.
- 19:43
- Unidentified speaker: They've built a reputation for innovation across both growth and income.
- 19:47
- Unidentified speaker: From the Hamilton Champions lineup of growth-focused ETFs to their yield maximizer strategies designed to generate attractive monthly income.
- 19:55
- Unidentified speaker: Hamilton ETFs has spent the past decade challenging convention, developing new investment solutions, and making sophisticated strategies more accessible to everyday investors.
- 20:08
- Unidentified speaker: Now, before we get to our first question, remember all of our charts are sponsored by Wealth Simple Trade, the self-directed trading platform built for active traders in Canada.
- 20:16
- Unidentified speaker: Wealth Simple Trade lets DIY traders chart, execute, and manage positions in a single view, all on a powerful commission-free trading platform.
- 20:24
- Unidentified speaker: You can snap the QR code on any of our charts, or if you're listening, you can click the link in the show notes.
- 20:30
- Unidentified speaker: Okay, our first question is on Pfizer, and I swear it's not from me, though.
- 20:34
- Unidentified speaker: I have been a long-suffering Pfizer shareholder.
- 20:37
- Unidentified speaker: Pfizer is perked up over the last few months.
- 20:39
- Unidentified speaker: What are your expectations for the stock?
- 20:41
- Unidentified speaker: This question coming from Fred in Hamilton.
- 20:43
- Unidentified speaker: And I actually checked my PA.
- 20:45
- Unidentified speaker: I'm still I'm all I'm down, but I'm only down 2%.
- 20:48
- Unidentified speaker: But it's it's perked up.
- 20:50
- Unidentified speaker: Pfizer is alive, at least, a little bit more alive than it was.
- 20:55
- Unidentified speaker: It looks like it was a decent quarter.
- 20:56
- Unidentified speaker: Is this one that you own?
- 20:58
- Unidentified speaker: It's not one that I own, which you know, in a 20, 20 large cap stock portfolio, I get questions.
- 21:04
- Unidentified speaker: At some point I'm gonna buy it again.
- 21:06
- Unidentified speaker: Um, and part of that's so that I have to stop defending why I don't own it.
- 21:11
- Unidentified speaker: Um but why, why, why we wouldn't own it would be, you know, when we look back to, I think it was the the C gen acquisition a number of years ago, it it, you know, COVID was a huge cash flow rush.
- 21:23
- Unidentified speaker: And so, but they knew that they had to backfill this pipeline.
- 21:29
- Unidentified speaker: And so that that still exists as we look out to 2028, 2028.
- 21:34
- Unidentified speaker: CGEN was a pivot into uh on yeah, oncology.
- 21:38
- Unidentified speaker: Yeah, yeah.
- 21:39
- Unidentified speaker: And uh PadSev, I think, is the uh the the primary drug that uh and so are we seeing signs that that worked?
- 21:45
- Unidentified speaker: I know like new products are helping.
- 21:47
- Unidentified speaker: They have, but they have, but they paid a huge premium for this.
- 21:50
- Unidentified speaker: And so I I can't remember if it was 20 times revenue or something like this.
- 21:55
- Unidentified speaker: Um but and and it was a big and so that was our concern back back then was okay, the RD productivity that we were measuring, so based on RD spend to new drug, uh new drug sales, and that what that was pre-COVID.
- 22:10
- Unidentified speaker: Um so COVID was a cash flow rush, so we kept it.
- 22:12
- Unidentified speaker: And then um that RD productivity for us was declining coming into COVID.
- 22:17
- Unidentified speaker: And then when we started to see that kind of resume uh post-COVID, and then realizing 2028, 2029, uh, I want to say extandee um in in prostate and eyebrance uh in their oncology, the number of drugs coming off patent, you know, you're seeing a fairly meaningful drop-off.
- 22:36
- Unidentified speaker: Um, and so that's what has given us pause.
- 22:40
- Unidentified speaker: The acquisitions being, you know, paying a lot for, you know, decelerating, uh, declining revenue coming out.
- 22:48
- Unidentified speaker: But the flip side is is the uh they do have a number of uh number of uh upcoming trials.
- 22:54
- Unidentified speaker: You know, it's a very large company.
- 22:55
- Unidentified speaker: They've got a number of blockbuster drugs.
- 22:58
- Unidentified speaker: So from a cash flow standpoint, I think that I want to say a six-handle on the dividend yield is probably a reasonable floor.
- 23:05
- Unidentified speaker: Um, last I checked, it's still called an 85% payout.
- 23:10
- Unidentified speaker: So, you know, it's not a risk-free di dividend.
- 23:13
- Unidentified speaker: And so, you know, I'd like I don't mind paying more to see a little bit more productivity on the RD side.
- 23:19
- Unidentified speaker: So it was a name we sold it about two years ago.
- 23:23
- Unidentified speaker: Uh, and at some point we'll own it again.
- 23:25
- Unidentified speaker: But for right now, let's see if we can build out that pipeline as that you know declining revenue coming out.
- 23:30
- Unidentified speaker: And oh, and you know, I didn't get a chance to ask you about RD because again, there was a time, there was an era.
- 23:37
- Unidentified speaker: Uh, the last time biotech was cool where we didn't care about RD spending.
- 23:41
- Unidentified speaker: It was just more like it was all growth by acquisition, right?
- 23:44
- Unidentified speaker: And that was the model.
- 23:45
- Unidentified speaker: And then that went away in a huge way.
- 23:48
- Unidentified speaker: Um, and I think is what really caused the sector to just meander around.
- 23:52
- Unidentified speaker: Now it sounds like is that a key focus for you?
- 23:55
- Unidentified speaker: Like just tried and true innovation.
- 23:57
- Unidentified speaker: How much are you spending on RD and what are you getting out of it?
- 24:00
- Unidentified speaker: And what are you paying for your acquisitions?
- 24:01
- Unidentified speaker: Absolutely.
- 24:02
- Unidentified speaker: That's always been so one of our key metrics we uh we chart out is RD to sales as well.
- 24:06
- Unidentified speaker: So we do want to see high RD um uh on our biotech and and pharma.
- 24:12
- Unidentified speaker: Uh and so, you know, look and the uh the Pfizer, I would say also, I would call it a value play.
- 24:19
- Unidentified speaker: And so not a value trap.
- 24:21
- Unidentified speaker: I I it's been a value trap.
- 24:24
- Unidentified speaker: So we need to see some, we need to see some value creation here, I think, uh, on the RD productivity.
- 24:30
- Unidentified speaker: And so, but with that, you'll get a couple of things.
- 24:32
- Unidentified speaker: You'll get people like me going, hey, do you know what?
- 24:34
- Unidentified speaker: Okay, their RD productivity is improving.
- 24:37
- Unidentified speaker: And you look at like a name like Bristol Myers, I put that in a similar type of category where it is a relatively deep value play and you're waiting for the catalyst to improve the multiple.
- 24:48
- Unidentified speaker: And so we see that with Bristol.
- 24:51
- Unidentified speaker: You know, it's had a it's had a pretty decent year over the past uh, you know, past 12 months.
- 24:56
- Unidentified speaker: And that's that's on multiple expansion.
- 24:58
- Unidentified speaker: It's gone from a seven times earnings to, you know, nine and a half times, still inexpensive.
- 25:03
- Unidentified speaker: But I would put that in a similar, I don't want to be over when we build out our portfolios.
- 25:07
- Unidentified speaker: I'm cognizant of subsector allocation, but also style.
- 25:10
- Unidentified speaker: And so for right now, we've we've got kind of our deep value play with Bristol.
- 25:14
- Unidentified speaker: Okay, talk to me about Moderna.
- 25:16
- Unidentified speaker: We got a question from Sergio.
- 25:17
- Unidentified speaker: The shares have soared um because of the company's cancer vaccine.
- 25:21
- Unidentified speaker: I also own this.
- 25:23
- Unidentified speaker: Can you tell?
- 25:23
- Unidentified speaker: I have a I love a broken, beaten down story.
- 25:27
- Unidentified speaker: Yeah, thankfully, I didn't own it since the pandemic.
- 25:30
- Unidentified speaker: I bought it after it it was down.
- 25:32
- Unidentified speaker: Um, and it it has absolutely ripped higher.
- 25:37
- Unidentified speaker: Yep.
- 25:37
- Unidentified speaker: This is a very volatile name.
- 25:40
- Unidentified speaker: Did you ever own it?
- 25:41
- Unidentified speaker: Would you own it here?
- 25:42
- Unidentified speaker: No, never, never owned it.
- 25:44
- Unidentified speaker: Uh into the pandemic.
- 25:45
- Unidentified speaker: Yeah.
- 25:46
- Unidentified speaker: And part of it is, you know, within those 20 stocks, we do have to satisfy some valuation metrics.
- 25:51
- Unidentified speaker: Um, and so Bravo for the uh, you know, a tremendous success-ish.
- 25:56
- Unidentified speaker: It's phase two.
- 25:57
- Unidentified speaker: Um, so uh, you know, it's a really exciting innovation that's happening in oncology.
- 26:03
- Unidentified speaker: And so, you know, they're they're calling it a vaccine, but it is, you know, it's for people that have had melon melanoma already.
- 26:11
- Unidentified speaker: And you know, so um it's almost like a treatment.
- 26:14
- Unidentified speaker: Uh yeah, therapeutic vaccine, if you will.
- 26:17
- Unidentified speaker: And so it's really, really exciting.
- 26:19
- Unidentified speaker: Now, the bears would argue that a lot of that has uh, you know, been baked in for a phase two, especially when they have not had as much success, you know, and and the the um mechanism of action has not had as much success in other earlier staged uh trials.
- 26:37
- Unidentified speaker: And so, but I'll ostracize that that, you know, I think I want to say it was like 45% improvement rate over just K-Truda alone, the treatment with K-Trude alone.
- 26:47
- Unidentified speaker: And what's what's exciting about that?
- 26:49
- Unidentified speaker: Merck does.
- 26:50
- Unidentified speaker: And so, you know, one way we're participating in this, the vaccine that they're they're working on with the mRNA technology is actually a culmination with K-Truda.
- 27:01
- Unidentified speaker: And so, you know, if you look at Merck, Merck is benefiting from this.
- 27:05
- Unidentified speaker: From our perspective, though, this would be exactly, you know, when when I look back pre-pandemic, you know, we want to try to avoid the, you know, the the rockets and torpedoes.
- 27:16
- Unidentified speaker: And so single.
- 27:18
- Unidentified speaker: See, this is a this has been both twice over versus we still participate some with K-Trude on Merck.
- 27:23
- Unidentified speaker: Now, Pfizer Moderna also got caught up in Maha, make America healthy again and post the midterms.
- 27:30
- Unidentified speaker: Uh specifically, Moderna is ripping higher.
- 27:33
- Unidentified speaker: Um, I know you said the midterms is just an event that has happened, but that was a real pall on the sector.
- 27:40
- Unidentified speaker: Vaccine rates in the US are falling.
- 27:43
- Unidentified speaker: Um, that's a problem if you're a vaccine maker.
- 27:46
- Unidentified speaker: Do you have any feeling that that trend will change and people will start to warm up to vaccines again?
- 27:53
- Unidentified speaker: Valid, valid question.
- 27:55
- Unidentified speaker: Um, and of course, this is uh this is the morning after uh the the uh the elections.
- 28:01
- Unidentified speaker: Uh and so that is a that is a possibility.
- 28:04
- Unidentified speaker: Uh again, you know, we'll we'll still benefit from some of the vaccines within with the companies like Merck again.
- 28:10
- Unidentified speaker: And like the FDA, the FDA got so politicized it felt like.
- 28:14
- Unidentified speaker: Um did you feel like it got politicized and it's look at damage with certain I think that that would just be more of a positive sentiment shift.
- 28:24
- Unidentified speaker: And so I want to say that the the um uh health and human services went from 95,000 staff to 72,000 staff in the past two years.
- 28:33
- Unidentified speaker: So I think they're probably starved for some scientific leadership and some of the some of the kind of you know, I it's less impactful for what we do on a day-to-day.
- 28:43
- Unidentified speaker: Okay.
- 28:43
- Unidentified speaker: Um, but I would say that having some a little bit more balance in there would make sense.
- 28:48
- Unidentified speaker: And so back to that political lightning rod, the the maha.
- 28:52
- Unidentified speaker: Um, you know, I that's what I see that as.
- 28:54
- Unidentified speaker: And so we might see I it's a it's a great question that uh that I hadn't really quantificated on yet.
- 29:00
- Unidentified speaker: But the vaccine side of the equation could be something where we actually see more vaccines being rolled out.
- 29:06
- Unidentified speaker: But that's the market's interpretation too.
- 29:08
- Unidentified speaker: But yeah, you have to actually see follow through.
- 29:10
- Unidentified speaker: We've got a question on CVS, very timely from Jeff.
- 29:13
- Unidentified speaker: What do you make of plans to spin off the drugstore?
- 29:16
- Unidentified speaker: I also own CVS.
- 29:19
- Unidentified speaker: And I bought it after it broke a couple of years ago.
- 29:22
- Unidentified speaker: Uh the market does not like this.
- 29:24
- Unidentified speaker: It does not like it.
- 29:26
- Unidentified speaker: So if you think about CVS, you think, well, it's just a pharmacy.
- 29:29
- Unidentified speaker: But as you said, it's got a whole managed care business.
- 29:31
- Unidentified speaker: Oh, yeah.
- 29:31
- Unidentified speaker: It's a, it's, it's got the CVS care mark, um, uh, and really the the at an acquisition, you know, put them into the insurance business.
- 29:40
- Unidentified speaker: Uh, and so, you know, look, I I've followed it for a number of years, you know, somewhat on the sidelines and peripherally, because when I look at our portfolio, I want best in class.
- 29:50
- Unidentified speaker: And from our perspective, in that, in that business, everybody is trying to get like United Health.
- 29:56
- Unidentified speaker: Everybody wants to be vertically integrated across these, these um, you know, business lines.
- 30:01
- Unidentified speaker: And so it just, it just, there's a lot of synergies within that.
- 30:05
- Unidentified speaker: And so I remember when CVS was talking about, oh, well, we're gonna put the, you know, we're gonna we're gonna drive, you know, retail traffic into the pharmacies by putting, you know, the um, you know, the the doctor's offices or the um the skilled nursing, you know, rate adjacent and inside the pharmacies.
- 30:23
- Unidentified speaker: And that was the transition a few years ago, where back to where you were saying, oh, well, it's a deep value play, and that's what's gonna cause the that's the catalyst for recovery.
- 30:31
- Unidentified speaker: And so from what I read just this morning, it just it was just announced their their earnings were okay.
- 30:36
- Unidentified speaker: Yeah.
- 30:37
- Unidentified speaker: I prefer United Health just from a totality perspective.
- 30:41
- Unidentified speaker: Um, and also that that view that the the retail is a little bit more of a drag.
- 30:46
- Unidentified speaker: Um, but the the street does not like this right now.
- 30:48
- Unidentified speaker: And uh again, even stores they get repackaged, put around like think about Walgreens, Boots Alliance, like the the Rex Alls of the World.
- 30:56
- Unidentified speaker: The Rex, like they are really they um they get passed around.
- 30:59
- Unidentified speaker: Passed around.
- 31:00
- Unidentified speaker: And and from CVS's perspective, um, you know, it's not an expensive stock, but yeah, uh, you know, I even even after the, I don't know if it's down five or 10% now.
- 31:11
- Unidentified speaker: Um, even after that, I'd still, I'm not looking at it going, oh, I'm gonna buy this because now they're gonna turn it around.
- 31:16
- Unidentified speaker: And on the contrary, this will be kind of to me, there's a lot of people that are like, well, you told us you were gonna do this to create the value and you did this.
- 31:24
- Unidentified speaker: And you told us you were gonna do this.
- 31:25
- Unidentified speaker: Now you're doing this.
- 31:26
- Unidentified speaker: Yeah.
- 31:27
- Unidentified speaker: I think there's probably some some people that are like, okay, we're we're gonna step aside now.
- 31:32
- Unidentified speaker: When you choose a Raymond James advisor, you're getting more than independent financial management.
- 31:37
- Unidentified speaker: You're getting access to complete financial guidance under one roof, from tax and estate planning to trust services for generational wealth and strategies for life's key milestones, like buying a home, funding your children's education, or preparing for retirement.
- 31:51
- Unidentified speaker: They bring it together in one financial plan.
- 31:54
- Unidentified speaker: What also makes Raymond James advisors unique is their complete independence.
- 31:58
- Unidentified speaker: With no proprietary product to promote, you will benefit from personalized services, all backed by the strength and resources of Raymond James, a powerhouse with a hundred billion in assets and over 520 advisors nationwide.
- 32:12
- Unidentified speaker: Discover how Raymond James can help you live a life well planned.
- 32:16
- Unidentified speaker: Visit RaymondJames.ca.
- 32:20
- Unidentified speaker: Support for this podcast is brought to you by EQB Inc., the parent company of EQ Bank, Canada's Challenger Bank.
- 32:25
- Unidentified speaker: For EQB, Challenger is more than just a slogan, it's a mindset.
- 32:29
- Unidentified speaker: Through EQ Bank, they built an award-winning digital first banking model designed to deliver more value, choice, and innovation to Canadians like you.
- 32:37
- Unidentified speaker: Now, EQB is scaling that strategy.
- 32:39
- Unidentified speaker: Its recent acquisition of PC Financial added credit cards to its banking suite and expanded its reach to more than 4 million customers.
- 32:46
- Unidentified speaker: EQ Bank is now the exclusive financial partner for the PC Optimum program, connecting it to more than 18 million members and integrating it deeper into Canadians' everyday lives.
- 32:56
- Unidentified speaker: It's a Canadian growth story powered by innovation, purpose, and a different way of thinking about banking.
- 33:01
- Unidentified speaker: EQB, the company behind EQ Bank, Canada's Challenger Bank.
- 33:05
- Unidentified speaker: We've got a question on Bosch Health, which is like the only Canadian name that you could own of any size in Canada.
- 33:11
- Unidentified speaker: Um, should I buy at these levels?
- 33:13
- Unidentified speaker: The question is from Raheem.
- 33:14
- Unidentified speaker: They just reported earnings and the stock popped, but another sort of like messy stock.
- 33:21
- Unidentified speaker: It's down way from the pandemic.
- 33:24
- Unidentified speaker: Um, if you covered it or if you followed it years and years ago, it's Valiant.
- 33:29
- Unidentified speaker: Sure.
- 33:30
- Unidentified speaker: It's the old Valiant and it's had several makeovers to try and get away from that hideous legacy.
- 33:35
- Unidentified speaker: It's an $8 stock now, it used to be a $200 stock.
- 33:38
- Unidentified speaker: Sure.
- 33:39
- Unidentified speaker: Peter Parker, I remember it well, the uh the questions that they had uh, you know, back uh back uh under Valiant.
- 33:45
- Unidentified speaker: Um and so look, uh I look at it in the one of my easy screens that I can look at is things like debt de bit duh.
- 33:52
- Unidentified speaker: And still too much debt?
- 33:54
- Unidentified speaker: Too much debt, too much debt.
- 33:55
- Unidentified speaker: And it's you know, it's great to see it recovering.
- 33:58
- Unidentified speaker: Um, you know, for me, I'm not looking for the turnaround story.
- 34:02
- Unidentified speaker: Uh, you know, that deep value we're gonna, you know, delever the balance sheet.
- 34:06
- Unidentified speaker: Um I occasionally I end up with one, uh, you know, because of an acquisition or something like that, where there it's a heavy balance sheet.
- 34:14
- Unidentified speaker: Stryker was like that a number of years ago after the uh they I think it was uh say Jude.
- 34:19
- Unidentified speaker: No, that was Abbott.
- 34:20
- Unidentified speaker: Um it was Abbott that the uh the the big uh the big debt that increased and we we were able to live with that.
- 34:26
- Unidentified speaker: Um, but you know, for something like this, I just look at a debt debit duh and go, no, it's it's not what I'm looking for.
- 34:32
- Unidentified speaker: It's a lot of debt still, like 20 billion over 20 billion debt for 11 billion sales.
- 34:37
- Unidentified speaker: There's there's a uh the the flip side is I was delighted, and I I haven't covered it yet, just hasn't hit our universe.
- 34:42
- Unidentified speaker: But I was delighted to see uh in part because my wife worked there as a as a chef many moons ago uh for Apotex.
- 34:49
- Unidentified speaker: And so for to see Apotex on the in the Canadian market, it's it's a you know, it's a generic you know, it's a generic and the margins and the growth tend to not be as uh as robust as some of the other areas.
- 35:02
- Unidentified speaker: But do you know what I'd love nothing more than to see, you know, I'll put it out there, lots more incentives for innovation in the medical fields, like you know, in Canada and also on the manufacturing side.
- 35:15
- Unidentified speaker: You know, let's bring more of that, you know, north.
- 35:18
- Unidentified speaker: Apotex has done well.
- 35:19
- Unidentified speaker: It's like one of the few IPOs A that we got, and definitely one that's at least above its uh IPO price.
- 35:25
- Unidentified speaker: It was twelve I think it went public at 24.
- 35:27
- Unidentified speaker: Now it's around 34.
- 35:28
- Unidentified speaker: Um, we have a question on Zoetis.
- 35:31
- Unidentified speaker: Should I pick it up?
- 35:32
- Unidentified speaker: Zoetis is a spin-off from Pfizer?
- 35:37
- Unidentified speaker: Uh was it Pfizer?
- 35:39
- Unidentified speaker: Many years ago.
- 35:40
- Unidentified speaker: Many, many years ago, but it's um it's like uh pet medicine.
- 35:45
- Unidentified speaker: Yeah, yeah.
- 35:47
- Unidentified speaker: Animal health.
- 35:47
- Unidentified speaker: And uh and then you so so two main business lines, which would be you kind of your livestock, if you will, uh, and then your companion animal, which is really where the growth driver has been.
- 35:58
- Unidentified speaker: Um we used to own it.
- 36:00
- Unidentified speaker: There was actually uh Pfizer was my last, I think Pfizer, I can't remember between the two of them if I sold Pfizer last or if I sold Zoetis last.
- 36:08
- Unidentified speaker: Um, but we we owned it for a number of years.
- 36:11
- Unidentified speaker: Um, I don't want to seem like I'm not technical, but one of the reasons that really why we looked at this and said we're not going to own it in a portfolio of 20 stocks, when those political lightning rods start lighting up, my animal health should be relatively immune to that.
- 36:29
- Unidentified speaker: And every time it happened, it wasn't.
- 36:31
- Unidentified speaker: So I felt like that there was something wrong.
- 36:33
- Unidentified speaker: And so when we peeled back the layer, um, the layers on the fundamentals, their animal, sorry, their companion um side, we start to think about a consumer that is, you know, feeling it at the pumps, feeling it, you know, at the grocery stores.
- 36:49
- Unidentified speaker: Now, one of the things we see is animal companion animals are one of the last things we spend on coming into recessions.
- 36:56
- Unidentified speaker: But there's no question that that's am I going to go a branded or a generic?
- 37:00
- Unidentified speaker: I'm probably going to start to shift to the generic.
- 37:02
- Unidentified speaker: Uh, and then I put on top of that their um their trio, um uh Symparico, I think it is, is seeing a fair amount of competition from Alanco.
- 37:12
- Unidentified speaker: And it's loaded earlier this year.
- 37:14
- Unidentified speaker: Alanco was the spin-out um a number of years ago.
- 37:19
- Unidentified speaker: Uh, I think that was Pfizer.
- 37:20
- Unidentified speaker: And so uh um, but the uh yeah, so seeing some competition there.
- 37:25
- Unidentified speaker: And Merck, ironically, though, is number three.
- 37:27
- Unidentified speaker: So, you know, when I think about a pharma that kind of is giving me a little bit of exposure, a little bit more diversity.
- 37:33
- Unidentified speaker: Um, but uh, but I'll be the first to admit I really like the company of Zoetis itself.
- 37:38
- Unidentified speaker: I just see competition and a consumer and the fact that uh, you know, it didn't do, didn't do what it should do when I needed it to do it and paying uh paying 30x multiple.
- 37:49
- Unidentified speaker: Uh, I think it's probably still a little bit rich after this balance that it's had.
- 37:53
- Unidentified speaker: Okay.
- 37:53
- Unidentified speaker: I mean, and it's still well off of where it was.
- 37:55
- Unidentified speaker: So you're not chasing it lower.
- 37:57
- Unidentified speaker: That's correct.
- 37:58
- Unidentified speaker: Um, we've got a question on MedTech, uh, which actually will lead us nicely into pro picks.
- 38:03
- Unidentified speaker: But first, I want to ask you a Boston Scientific.
- 38:06
- Unidentified speaker: Should I keep holding?
- 38:07
- Unidentified speaker: That was one of those names, right?
- 38:09
- Unidentified speaker: You it's been one of those days.
- 38:11
- Unidentified speaker: I've I've owned them before and I own it right now, and it has been a been a painful spot to uh painful spot to be.
- 38:18
- Unidentified speaker: And uh look, I go back, call it, call it 18 months ago.
- 38:23
- Unidentified speaker: There is this company was a company that could not do any wrong from a from a management perspective.
- 38:30
- Unidentified speaker: Every quarter for I want to say, you know, six years, not one missed quarter, no margin compression.
- 38:38
- Unidentified speaker: Um, you know, they had a couple acquisitions that uh you know and it'll escape me what which ones they were, but they you know, debt levels came up a little bit.
- 38:45
- Unidentified speaker: So there was there was a little bit of that, but then ultimately they have uh they have a technology.
- 38:51
- Unidentified speaker: So they they they do a lot of cardiovascular um and uh and and kind of think about your pacemakers, that type of uh type of thing.
- 38:59
- Unidentified speaker: And uh so they they had some uh they had some um misgrowth on their watchmen, uh, which was uh which um I think left the atrial uh fib atrial appendage.
- 39:13
- Unidentified speaker: Um and uh uh but then the their their AFib treatment, which is um the electro uh uh what's the word I'm looking for?
- 39:23
- Unidentified speaker: I'm having a little bit of a moment here.
- 39:25
- Unidentified speaker: Um uh bad school.
- 39:28
- Unidentified speaker: No, no, that's right.
- 39:29
- Unidentified speaker: I'm sorry, they're PFA, their pulse field ablation.
- 39:32
- Unidentified speaker: Uh part of a pulse field ablation for uh for AFib, um, which is a new technology to treat AFib, which really just means you're damaging less cells as you go in to treat this um compared to freezing or burning.
- 39:47
- Unidentified speaker: And so um, you know, wonderful new technology, but Medtronic and Johnson Johnson are coming in.
- 39:54
- Unidentified speaker: So we've seen a lot of competition there.
- 39:57
- Unidentified speaker: Um and so with that, the growth has come down.
- 40:01
- Unidentified speaker: They've had to reduce their guidance a few times.
- 40:04
- Unidentified speaker: It's caused the street a lot of angst to see that guidance come down, you know, not once, but it's been three quarters, you know.
- 40:11
- Unidentified speaker: And so when we look at that and we say, that's not great, but it's multiple has also come in, you know, all like literally been cut in half, you know, from a from, you know, I think we're we're sitting at about 18, yeah.
- 40:24
- Unidentified speaker: Yeah, depending on the on the the estimate.
- 40:26
- Unidentified speaker: And so versus, you know, you were sitting up at 36 for a premier top end uh med tech.
- 40:32
- Unidentified speaker: I guess the question you have to ask yourself is is it gonna get back there?
- 40:35
- Unidentified speaker: Are these quarter quarter to quarter issues and ultimately they'll fix it?
- 40:41
- Unidentified speaker: What's your view?
- 40:42
- Unidentified speaker: Uh I think they do.
- 40:43
- Unidentified speaker: Uh, and I think they have have the you know, the background on innovation going back really, you know, past 15 years.
- 40:52
- Unidentified speaker: I think they do that.
- 40:54
- Unidentified speaker: Um the the med techs have been a little bit out of favor already.
- 40:58
- Unidentified speaker: Uh, so that's compounding, compounding, you know, the the reduced guidance.
- 41:03
- Unidentified speaker: So at these levels, at these valuations, I'm good to own it.
- 41:08
- Unidentified speaker: Uh, but I also own Medtronic, which took some market share from them as well.
- 41:11
- Unidentified speaker: So the power of diversification in this sector is really important.
- 41:15
- Unidentified speaker: And we're gonna see that because you brought another MedTech as one of your ProPix.
- 41:19
- Unidentified speaker: So let's get into that now.
- 41:26
- Unidentified speaker: ProPix is brought to you by ATB Financial.
- 41:29
- Unidentified speaker: With over $100 billion in assets, ATB Financial is powering possibilities for more than $843,000 financial services clients.
- 41:38
- Unidentified speaker: ATB Cormar Capital Markets is a leading North American investment firm providing holistic corporate and capital markets advice and full service financial solutions.
- 41:47
- Unidentified speaker: Visit ATB.com slash in the money for more information.
- 41:51
- Unidentified speaker: Okay, so uh you're all you own MedTech, you own it through Boston Scientific and Medtronic, but you also own it through Stryker.
- 41:59
- Unidentified speaker: And Stryker is interesting because the stock recently has acted a little bit better, but it just lowered its forecast.
- 42:06
- Unidentified speaker: Um, it does something different than Boston Scientific, which is more cardio.
- 42:10
- Unidentified speaker: Stryker is more hips and knees.
- 42:12
- Unidentified speaker: Is that a fair assessment?
- 42:14
- Unidentified speaker: A fair assessment.
- 42:14
- Unidentified speaker: I I've the way I explain Stryker, I love it because uh um I think about my dad was a surgeon and I think about him in the OR room.
- 42:22
- Unidentified speaker: I can't imagine him.
- 42:23
- Unidentified speaker: That's why you want to get all these names, right?
- 42:25
- Unidentified speaker: Right, exactly.
- 42:26
- Unidentified speaker: That's right.
- 42:27
- Unidentified speaker: So, but I think of him uh, and you know, he's not reaching over going, pass me the DeWalt.
- 42:32
- Unidentified speaker: You know, so when I think about the operating room and a lot of the the tools, and you know, even the ENT specialists that, you know, they they they've got a hundred-page booklet of different types of uh equipment.
- 42:44
- Unidentified speaker: Uh when uh, you know, when I've uh when I've seen people on the stretchers going into the ambulance, they're striker.
- 42:50
- Unidentified speaker: So you start to think about the totality of of what they're doing.
- 42:54
- Unidentified speaker: So uh the a key component of their business, though, is um orthopedics, uh hips and knees.
- 43:00
- Unidentified speaker: And so that has been a little bit slower uh this year.
- 43:05
- Unidentified speaker: Um what we do, we do like their Mako system, soft tissue for uh for robotic assisted surgeries.
- 43:12
- Unidentified speaker: That's really exciting.
- 43:13
- Unidentified speaker: Uh, and so again, when we think about that, that multiple and the valuation they're paying for this, they did have to reduce guidance on that, but they also had a cyber attack, uh which, you know, the str I was kind of surprised to see the street kind of, oh, I can't believe they missed on the cyber.
- 43:29
- Unidentified speaker: It's like you kind of knew that was happening.
- 43:31
- Unidentified speaker: Um, but nonetheless, you know, I would say, you know, solid balance sheet.
- 43:36
- Unidentified speaker: Does it does a cyber attack um create a a risk of who are the buyers, like hospitals or you know, a saying, well, maybe one won't go with strike?
- 43:47
- Unidentified speaker: Yes, yeah, effectively.
- 43:49
- Unidentified speaker: That's that's the that is that is the concern.
- 43:51
- Unidentified speaker: I'm going to get these from Johnson and Johnson, or you know, I'm going to get them from uh from somebody else.
- 43:58
- Unidentified speaker: Um and so at the same time, you've also got some sowing demand uh in orthopedics.
- 44:03
- Unidentified speaker: And so perhaps that's a little bit of, you know, the consumer feeling a bit of the heat on uh on inflationary pressures as well.
- 44:10
- Unidentified speaker: So I think there's a bit of that um, you know, caught up a little bit in the trade war as well, uh, with some globally diversified manufacturing.
- 44:19
- Unidentified speaker: So we put all those together and we say those are I I think those are transient.
- 44:23
- Unidentified speaker: Uh, and you've just got this, you know, well-diversified company that, you know, has been beaten up the valuation multiple again.
- 44:30
- Unidentified speaker: I looked at it uh uh uh before earnings.
- 44:33
- Unidentified speaker: Um, and it was uh it was the lowest we've seen since uh since the pandemic.
- 44:38
- Unidentified speaker: Wow.
- 44:38
- Unidentified speaker: So you've seen, you know, basically, you know, you're at you're at, you know, call it 12, 15 year lows in valuations for an area that maybe needs to, maybe needs to chew through one, maybe two more quarters to really get sort of a viewpoint into, you know, the next year or even into 2028 outlook.
- 44:56
- Unidentified speaker: Okay, that's good perspective.
- 44:57
- Unidentified speaker: And all the picks you brought to us are from like a little sampling from each different sector within healthcare.
- 45:02
- Unidentified speaker: So this was the Medtech sample.
- 45:04
- Unidentified speaker: You said at the beginning of the year, uh, you would have thought maybe pharma's not gonna be what carries my portfolio.
- 45:10
- Unidentified speaker: And it did.
- 45:11
- Unidentified speaker: And one of your holdings was AbVee, and you've brought that to us.
- 45:14
- Unidentified speaker: And Abvi's had a stellar year.
- 45:17
- Unidentified speaker: Um, you know, the stock is moving nicely up and to the right.
- 45:20
- Unidentified speaker: What is key?
- 45:21
- Unidentified speaker: What has been key to AbVee uh outperforming, especially, you know, as you said, since that June time period.
- 45:29
- Unidentified speaker: And I'm pretty sure I'm gonna check it out.
- 45:31
- Unidentified speaker: Yes, like close to a record high.
- 45:33
- Unidentified speaker: Yeah.
- 45:34
- Unidentified speaker: So uh uh, and um it's gonna skate me the spin out 15 years ago as well for uh where they get spit out from.
- 45:40
- Unidentified speaker: Uh and so uh look at Abvi, uh I think one of the things we really like here, well, a diversified large biotech.
- 45:48
- Unidentified speaker: Um and they Abbott.
- 45:50
- Unidentified speaker: Uh it was Abbott, thank you.
- 45:51
- Unidentified speaker: Yeah.
- 45:51
- Unidentified speaker: Um and so uh so look at you know, well-diversified large cap biotech.
- 45:57
- Unidentified speaker: That's one thing that we like, you know, and we like what they did with their cash flow wins, if you will.
- 46:04
- Unidentified speaker: So um Humira was the largest selling biotech.
- 46:09
- Unidentified speaker: It was $20 plus billion dollars a year for this drug used for multitude of various types of indications and immunological indications of, you know, think about uh your IBD or or psoriasis, et cetera.
- 46:21
- Unidentified speaker: Now that went off path patent, I want to say, you know, about a year and a half, maybe two years ago.
- 46:27
- Unidentified speaker: Uh and so the biggest concern, you saw this stock getting, you know, hit pretty hard on the back of kind of like Pfizer, you know, it's going off patent.
- 46:35
- Unidentified speaker: What what does that mean now?
- 46:37
- Unidentified speaker: And so how are they going to build out those revenues?
- 46:40
- Unidentified speaker: So when we go back even further, you know, they'd already been thinking about a lot of this.
- 46:45
- Unidentified speaker: And so um building out on their RD side, making some acquisitions.
- 46:49
- Unidentified speaker: So you might remember an allergan, for example, which uh which was Botox.
- 46:54
- Unidentified speaker: So um if uh if anybody's wondering who makes Botox and all the different types of aesthetics, Allergan.
- 47:01
- Unidentified speaker: Allergan, which was which is now in Abvis um Abvy's portfolio.
- 47:06
- Unidentified speaker: So very well diversified.
- 47:08
- Unidentified speaker: Um and so, but more importantly, they've got uh they've got two other kind of blockbuster drugs, uh, which is Skyrizi and Rinvoke.
- 47:16
- Unidentified speaker: Yeah.
- 47:16
- Unidentified speaker: Uh and so treating similar types of indications as what Humira does, uh, but just better efficacy.
- 47:23
- Unidentified speaker: Oh, yeah.
- 47:24
- Unidentified speaker: And so, you know, they've been able to offset in some indications, not all, uh, they've been able to offset a lot of that patent decline by innovation.
- 47:34
- Unidentified speaker: And that's what I get excited about.
- 47:35
- Unidentified speaker: And hence, you know, you go back to when when it does work and you have these low multiple stocks, you know, that are able to execute on this on a strategy of building out and building for growth, you not only get that earnings growth accelerating, which is positive for your share price, but the market's willing to pay more for it.
- 47:55
- Unidentified speaker: So you have had some nice multiple expansion, but still inexpensive on the market.
- 47:58
- Unidentified speaker: You think it continues?
- 47:59
- Unidentified speaker: I think it does, yeah.
- 48:00
- Unidentified speaker: The final pick is United Health, Managed Care Turnaround.
- 48:04
- Unidentified speaker: Do you think I bought it?
- 48:07
- Unidentified speaker: I did buy it.
- 48:08
- Unidentified speaker: It did you good for you.
- 48:09
- Unidentified speaker: I did buy it.
- 48:10
- Unidentified speaker: I'm up 30, I think 35% uh since I bought it because I love a broken story in healthcare.
- 48:16
- Unidentified speaker: And you know, as I said, it's come back, but it's still off of what it was.
- 48:20
- Unidentified speaker: And maybe it's worth recapping just how United Health fell, you know, fell out of favor.
- 48:26
- Unidentified speaker: Sure.
- 48:27
- Unidentified speaker: And what it takes to get back into favor.
- 48:29
- Unidentified speaker: So there was uh there was a law going on, uh call it about uh about 18, 18, 24 months ago within the managed care subsector.
- 48:38
- Unidentified speaker: And so specifically on insurance, and there were some changes in in regulations on what are we, what what are the companies allowed to screen for?
- 48:47
- Unidentified speaker: And so the the analogy I use is, you know, they changed you, you can no longer screen, screen for pinky finger disease, for example.
- 48:56
- Unidentified speaker: And so, uh, but it turns out that a lot more people were coming in with these indications that they were not able to screen for.
- 49:03
- Unidentified speaker: And so that just meant that, and it wasn't just United, but it was across across the industry.
- 49:08
- Unidentified speaker: And what that meant was their medical loss ratios, which is how much they spend on their uh, you know, of their insurance premiums.
- 49:16
- Unidentified speaker: They're mandated to spend a certain amount, but that just meant they were spending more than they had forecast on treatments for people.
- 49:25
- Unidentified speaker: And so the market really punished the whole sector.
- 49:29
- Unidentified speaker: You then had some very negative um uh sentiment towards the sector.
- 49:35
- Unidentified speaker: You know, I won't get into all the details on why.
- 49:37
- Unidentified speaker: People that are familiar with the industry will understand, but that already calm that just compounded.
- 49:42
- Unidentified speaker: Then you had um, I think it was the Department of Justice came in and said, we're going to investigate.
- 49:48
- Unidentified speaker: No, it was actually in, I think I can't remember if it was a Wall Street Journal reporter Times that said they're being investigated for fraud, which that's how United Health found out as well.
- 49:59
- Unidentified speaker: And so uh that, you know, the the likelihood of that at the time from our perspective was was extraordinarily low.
- 50:07
- Unidentified speaker: Look, they they insure 50, 50 million lives in the US.
- 50:10
- Unidentified speaker: They're the largest integrated insurer.
- 50:13
- Unidentified speaker: Uh, and so they are going to get that every now and again.
- 50:17
- Unidentified speaker: They are going to have those political winds come in.
- 50:19
- Unidentified speaker: And when it rains, there's lightning towards them.
- 50:22
- Unidentified speaker: And so that is what happened.
- 50:24
- Unidentified speaker: We've seen a recovery.
- 50:26
- Unidentified speaker: We figured that was going to be the case because these um uh pools that they're insuring are effectively, they go, they go back and forth, especially with Medicare.
- 50:36
- Unidentified speaker: They do that every year.
- 50:37
- Unidentified speaker: And so they can go, oh, the these treatments, we we misinterpreted how many people were going to have that.
- 50:43
- Unidentified speaker: So we need to readjust for next year.
- 50:45
- Unidentified speaker: Price at higher.
- 50:46
- Unidentified speaker: You like the new CEO?
- 50:47
- Unidentified speaker: Because there was a CEO change as a result, yeah.
- 50:50
- Unidentified speaker: Uh, of all of this, and you think they're exact.
- 50:52
- Unidentified speaker: I think actually United raised its forecast, which Yeah, it was a fabulous quarter, and and the market really didn't give it much.
- 50:59
- Unidentified speaker: So so they kick off earnings season every year, and uh I can't wait to be done earnings season.
- 51:04
- Unidentified speaker: We're almost done.
- 51:04
- Unidentified speaker: We're about 80%.
- 51:06
- Unidentified speaker: And you said across the market, it's been a great earnings season.
- 51:09
- Unidentified speaker: It's you don't just get don't miss the loop.
- 51:12
- Unidentified speaker: Don't don't miss because if you missed this quarter, you're getting punished.
- 51:15
- Unidentified speaker: But they had a fabulous quarter.
- 51:17
- Unidentified speaker: And the outlook for the company, I think, as we start to look out now with, you know, the the questions about okay, do we see a little bit more, you know, of of the democratic sort of Medicare for all?
- 51:28
- Unidentified speaker: Uh I don't think that's going to uh I don't think that's going to impact them.
- 51:32
- Unidentified speaker: I think the market's going to look at this and say, hey, do you know what the propensity for more people to be insured now uh outweigh and propensity for more potential treatments?
- 51:43
- Unidentified speaker: Um, I think that's going to weigh any sort of um excise they might have to pay for premiums.
- 51:49
- Unidentified speaker: It's been great to have you on the show.
- 51:50
- Unidentified speaker: Before we let you go, we like to ask our guests for the closing bell, what do you like to do for fun?
- 51:56
- Unidentified speaker: Oh, for fun.
- 51:56
- Unidentified speaker: I love the gym.
- 51:57
- Unidentified speaker: Oh yeah.
- 51:58
- Unidentified speaker: Do you know what?
- 51:59
- Unidentified speaker: I if I can get there, if I can spend hours at the gym, I do.
- 52:02
- Unidentified speaker: Uh like deadlifting.
- 52:03
- Unidentified speaker: I uh yeah, do you know what legs and uh I know I haven't been there in the past of as much as I want to, uh, but I try to get in four or five days a week.
- 52:11
- Unidentified speaker: Yeah, that's it.
- 52:11
- Unidentified speaker: Yeah, yeah, that's I love uh the heavier the better.
- 52:14
- Unidentified speaker: Wow, and you don't get injured?
- 52:16
- Unidentified speaker: I I do.
- 52:16
- Unidentified speaker: And when you get injured as you get older, I uh I'm a testament to spending more on healthcare because when you get injured, it hurts longer.
- 52:24
- Unidentified speaker: You're gonna make strikers uh hit replacement.
- 52:27
- Unidentified speaker: No, I hope that doesn't happen for you.
- 52:28
- Unidentified speaker: But Paul, thank you so much for joining us on this show.
- 52:37
- Unidentified speaker: The closing bell is sponsored by the Halliburton Post House.
- 52:40
- Unidentified speaker: Great ideas deserve an extraordinary setting.
- 52:43
- Unidentified speaker: Nestled in Ontario's beautiful Halliburton Highlands, the Halliburton Post House offers exclusive lakeside executive retreats.
- 52:50
- Unidentified speaker: Imagine an entire boutique property reserved just for your team.
- 52:54
- Unidentified speaker: No distractions, just newly renovated accommodations, 15 guest rooms, exceptional dining, and inspiring spaces to connect, collaborate, and recharge.
- 53:04
- Unidentified speaker: Now booking for fall 2026 and 2027 retreats.
- 53:08
- Unidentified speaker: Mention in the money and receive $1,000 off your booking.
- 53:11
- Unidentified speaker: For more, go to Halliburton Posthouse.ca.
- 53:16
- Unidentified speaker: We'll always love talking about healthcare.
- 53:19
- Unidentified speaker: Don't worry, we're going back to resources on the next episode.
- 53:22
- Unidentified speaker: We've got Ben Mois Gervais.
- 53:24
- Unidentified speaker: He's the co-head at McKenzie's resource and energy evolution team.
- 53:29
- Unidentified speaker: Get your questions in now.
- 53:30
- Unidentified speaker: You can email us questions at inthemoneypod.com.
- 53:33
- Unidentified speaker: Find us anywhere on social media at in the money pod, and we'll see you on the next episode.
More from In the Money with Amber Kanwar
Jeff Currie's Big Shift: Short Commodities, Long the Companies
Episode discussion: Jeff Currie argues for shorting copper and owning energy equities over commodities amid geopolitical fragmentation
Speakers’ claims: Jeff Currie critiques the Bloomberg Commodity Index for including natural gas and recommends the GSCI or Quantix Commodity Index instead. He confirms a recent tactical shift to short copper due to near-term dollar strength and destocking, while maintaining a long-term bullish view on structural deficits. Currie contrasts the high free cash flow yields of major oil companies with negative yields for hyperscalers, suggesting a leadership rotation toward energy. He also discusses the impact of geopolitical fragmentation on commodity trends and highlights the operational success of ABEX exchange.
The Death of Canadian Small Caps: What Happens Next?
Episode discussion: Jeff Tory and guest discuss Canadian small cap underperformance, structural market shifts, and specific stock analyses.
Speakers’ claims: Jeff Tory of Pembroke Management argues that Canadian small caps have suffered a two-decade decline due to pension fund liberalization in 2006 and a shift from retail to institutional investing, leaving valuations at historic lows. He contrasts this with the high capital needs of public tech giants and highlights Pembroke's independent, value-oriented culture. The discussion expands to include specific Canadian equities, with the guest analyzing Cineplex's balance sheet, EQB's mortgage risks, CAE's turnaround potential, and Stingray's growth in digital advertising. The segment concludes with an examination of AGF Management's private asset valuation and Western International Investments' insurance holding strategy.